Journal of Neural Transmission

, Volume 116, Issue 3, pp 333–338

Do polymorphisms in transcription factors LMX1A and LMX1B influence the risk for Parkinson’s disease?

Authors

    • Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of Gothenburg
  • Anna Håkansson
    • Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of Gothenburg
  • Lars Westberg
    • Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of Gothenburg
  • Andrea Carmine Belin
    • Department of NeuroscienceKarolinska Institutet
  • Olof Sydow
    • Department of Clinical NeuroscienceKarolinska Institutet
  • Lars Olson
    • Department of NeuroscienceKarolinska Institutet
  • Björn Holmberg
    • Department of Clinical Neuroscience and Rehabilitation, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of Gothenburg
  • Laura Fratiglioni
    • The Aging Research CenterKarolinska Institutet
  • Lars Bäckman
    • The Aging Research CenterKarolinska Institutet
  • Elias Eriksson
    • Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of Gothenburg
  • Hans Nissbrandt
    • Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of Gothenburg
Movement Disorders - Original Article

DOI: 10.1007/s00702-009-0187-z

Cite this article as:
Bergman, O., Håkansson, A., Westberg, L. et al. J Neural Transm (2009) 116: 333. doi:10.1007/s00702-009-0187-z

Abstract

The key symptoms of Parkinson’s disease (PD) are caused by degeneration of dopamine neurons originating in substantia nigra. Whereas, transcription factor LMX1A is crucial for the differentiation of mesencephalic dopamine neurons, LMX1B appears to be important for both the development and the survival of these cells. The aim of this study was to investigate if genetic variation in LMX1A and LMX1B differs between patients with PD (n = 357) and control subjects (n = 1428) by genotyping 33 single nucleotide polymorphisms (SNPs) in LMX1A and 11 SNPs in LMX1B. Three SNPs in LMX1A and one in LMX1B were associated with PD. After splitting for gender, six SNPs were associated with PD in women and four in men. The significances obtained did not survive correction for multiple testing, and our results should hence be interpreted with caution, but are partly in line with a previous report, and should thus be of sufficient interest to encourage further studies of these genes in PD.

Keywords

Parkinson’s diseaseLMX1ALMX1BSNPsAssociation studyNeuronal development

Copyright information

© Springer-Verlag 2009